Tue, Sep 30, 2014, 2:24 PM EDT - U.S. Markets close in 1 hr 36 mins

Recent

% | $
Quotes you view appear here for quick access.

Oncolytics Biotech Inc. Message Board

bgzcle 70 posts  |  Last Activity: 22 minutes ago Member since: Aug 1, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    we saw power of bad news yesterday

    by stockpush98 49 minutes ago

    What was the bad news yesterday, they manipulated by dumping stock into a short position, but I did not see or hear anything negative about the company or product of Alcobra. If you were scared off, you may have followed the leader dump. I did not, still long and a little less strong, down some dollars. STILL .. Looking for a big comeback on the 3rd or 5th after FDA review. If their was bad news leaked, the board would be closed and the stock price at $2-4.00. You know shorts are not looking for successful companies, they are just looking for a buck, a million, or a billion. Don't let them suck you in, remember you may be down but your never out until you have sold. Their are not many shares of ADHD, so whatever trades their are usually huge swings. Stay cool don't panic and watch for some great news soon.

  • Reply to

    Market Manipulation rules 575

    by bgzcle 6 hours ago

    The more that know the more reporting that will be done, eventually something will happen that will make brokerage houses report it or suffer severe consequences.

  • Just last month the CME announced its new Rule 575. Effective September 15, it essentially says:

    DISRUPTIVE PRACTICES - It shall be unlawful for any person to engage in any trading, practice, or conduct on or subject to the rules of a registered entity that -

    (A) violates bids or offers; (B) demonstrates intentional or reckless disregard for the orderly execution of transactions during the closing period; or (C) is of the character of, or is commonly known to the trade as, "spoofing" (bidding or offering with the intent to cancel the bid or offer before execution).

    Wow. In sifting through the detail of the new rules, here's what especially stood out in its explanations:

    Once the smaller orders are filled, the market participant cancels the large orders that had been designed to create the false appearance of market activity. Placing a bona fide order on one side of the market while entering order(s) on the other side of the market without intention to trade those orders violates Rule 575.

    And further...

    A market participant places a large quantity of orders at the beginning of the pre-opening period in an effort to artificially increase or decrease the IOP with the intent to attract other market participants...

    It gets more specific from there.

    So there you have it. The CME itself detailing exactly the type of market manipulation that they know has gone on, and now specifically outlaw.

  • Let's hope for pre-continuation and a strong opening.

  • This is not the end, it's the beginning. Just need to understand three tests are underway Fragile X Pediatric ADHD and Adult ADHD. I'm ore of a believer one or more of these will be successful. No reason not too. Stock manipulation goes on with most all Bios and is a direct result of Hedge shorting. They bet every new issue is a failure and if it is not they like to inflict pain on long investors who are usually in it for more than just a fast buck. Sooner or later the rules for them will be adjusted and their greed made more difficult. Here is wahr we got going on .. Keep the Faith ... The FDA granted "Orphan Drug" designation to Metadoxine in the treatment of Fragile X Syndrome in December 2013.
    The Phase IIb Fragile X trial is a multi-center, randomized, placebo-controlled study and is being conducted in 11 clinical sites, primarily in the U.S. It is designed to investigate MDX for 6 weeks compared with placebo in 60 adolescent and adult subjects with Fragile X Syndrome.
    "We expect that this study will give us important insights into the efficacy and safety of MDX in Fragile X Syndrome," said Elizabeth Berry Kravis, MD, PhD, Associate Professor of Biochemistry, Neurological Sciences, and Pediatrics at Rush University Medical Center, and the Principal Investigator of the Phase IIb study. "Fragile X Syndrome is a genetic condition that causes intellectual disability, and is the leading known genetic cause of autism. There are no approved treatments for Fragile X Syndrome, so the development of MDX in this indication has the potential to address a significant unmet need."
    The trial is expected to complete enrollment and report topline data by the end of 2014.
    Also, The Phase IIb trial is a multi-center, randomized, double-blind, fixed dose study designed to evaluate the safety and tolerability of MDX in up to 82 adolescents (aged 13-17) with predominantly inattentive ADHD (PI-ADHD). The primary endpoint will be safety, tolerability and pharmacokinetics. Secondary endpoints include change in efficacy measures such as TOVA (Test of Variables of Attention), Wechsler Intelligence Scale for Children (WISC-IV) subtests, and working memory and processing speed. ClinicalTrials.gov Identifier: NCT02189772
    The trial is expected to complete enrollment and report topline data by the end of 2014

  • derrick .... So if you are out, #$%$ are you writing your irritating statements all over this board for? Who are you trying to convince and of what, or what is your point as someone else asked earlier? We all take responsibility for our own positions win or lose, but we don't scream hurrah when winning or cry about it when losing. Grin and bear it or just leave without commentary.

  • Reply to

    TNXP News

    by biradamin Sep 29, 2014 9:43 AM
    bgzcle bgzcle Sep 29, 2014 11:59 AM Flag

    Bird .. The market is hardly controlled by investors, it's controlled by naked shorts, hedge funds and brokerage houses. What I don't understand is why you need to tell this board how worried you are and give it your odds. If worried, than you should sell for lack of confidence and save your money. This is Vegas the way the market is today, product matters not, Hedge funds would kill a potential and helpful product shorting it for a buck. If you don't like gambling than you need to leave. Good news will not even guarantee a good price. Most every Bio that had success with product this past year has been shorted tot he point no individual longs really want to invest, their is no money in it even for the long term, if hedge shorts stay in it. The SEC and the Justice Department have to clean this up, or individuals will get wiped out and/or leave forever. Of course the problem is every Congressman has a hedge fund investment and they are making money so their is no need for them to legislate anything for the little investor. If I were you and I was as scared as you seem to be I would pull out.

  • Reply to

    TNXP News

    by biradamin Sep 29, 2014 9:43 AM
    bgzcle bgzcle Sep 29, 2014 10:30 AM Flag

    Bird .. nice try but you are the short here, probably naked too

  • September 27 Washington Post article under business. northwest-biotherapeutics-stock-woes-highlight-the-harm-of-short-sales ... Finally exposed in mainstream media. You can find the full story.

  • Search this article at the washington post. biotherapeutics-stock-woes-highlight-the-harm-of-short-sales dated September 27. Finally reputable source calls out bio bloggers and so called reporters from the street along with hedge funds and brokerage houses

  • Reply to

    Price Targets

    by xmdshrave Sep 25, 2014 7:54 PM
    bgzcle bgzcle Sep 25, 2014 8:27 PM Flag

    October 3 is only Phase3 top line may not get bump up .... only get bump down if negative. PFUDA 2015 date will be the big one if it looks successful.

  • Reply to

    hedge funds usually know

    by derrick911smith Sep 25, 2014 3:34 PM
    bgzcle bgzcle Sep 25, 2014 7:11 PM Flag

    Phase3 success will prop up the PPS ... t will remain a great day trade because of the limited shares until FDA PFUDA 2015

  • Reply to

    Short commentators taking over the ADHD Board here

    by bgzcle Sep 24, 2014 1:37 PM
    bgzcle bgzcle Sep 24, 2014 7:44 PM Flag

    ARNA OREX and TEVA all started at zero, a one horse pony and now they are growing. ADHD will be a buyout candidate, even the company is looking for a someone to buy based on good news.

  • When things are probably going to be just great for ADHD, shorts always come out of the hole to try to make you think differently for their own gains. Shorts never consider humanity and medications that might help people in life, they are only driven by the gamble of ruining a stock or even a company for a few bucks in their pocket. They should be in Vegas, but they know they can't steal from a casino and get away with it. They just post and post more the closer a deadline comes to a stock interest and their goal is to always make you want to doubt yourself and usually sell into their short position. I've always figured shorts to be pessimistic about life in general. They are always around to hang on to make companies losers. Can't wait to count the thumbs down....

  • Bears vs Bulls .. you can google search ... News for the street story 12889667 (insightful) by AF .. titled Why Alcobra Investors Are So Nervous About a Coming Drug Study

  • Reply to

    When Do They Report Latest Results?

    by webspecker Sep 23, 2014 1:04 PM
    bgzcle bgzcle Sep 24, 2014 9:10 AM Flag

    http://www.madinamerica.com/2014/08/adhd-treatment-market-value-reach-9-9-bn-2020/

  • Reply to

    Analyst and weathermen

    by gclark26 Sep 23, 2014 10:59 AM
    bgzcle bgzcle Sep 23, 2014 12:32 PM Flag

    May have been an NCI Study .. but I remember two thing, results delivered by BT and at the end he stated his enthusiasm for the results, guess he was the only one enthusiastic. What is he doing to stop the bleeding. This is as low as the PPS has been since listing. If you bought 20 years ago and held the whole time, you now have a loss. That's called a negative return on investment. If you bought at any other time and held, you are probably losing a great deal of money. BT broke it, now he must fix it and he knows it.

    Sentiment: Strong Sell

  • We get numbers for diet .. how about intercourse?

  • Reply to

    IMS 9/12/14

    by r1t2003 Sep 19, 2014 1:53 PM
    bgzcle bgzcle Sep 21, 2014 9:31 AM Flag

    Does anyone publish the number of prescriptions filled for Stendra?

  • bgzcle bgzcle Sep 20, 2014 4:27 PM Flag

    Think you should contact BT by email and ask him to respond. He is the only one that can.

ONCY
0.5699+0.0069(+1.23%)2:23 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.